129 related articles for article (PubMed ID: 9792297)
1. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells.
Lanza F; Castoldi GL; Castagnari B; Todd RF; Moretti S; Spisani S; Latorraca A; Focarile E; Roberti MG; Traniello S
Br J Haematol; 1998 Oct; 103(1):110-23. PubMed ID: 9792297
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts, and normal hemopoietic cells.
Lanza F; Castagnari B; Rigolin G; Moretti S; Latorraca A; Ferrari L; Bardi A; Castoldi G
Leukemia; 1997 Oct; 11(10):1700-10. PubMed ID: 9324292
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometry evaluation of urokinase-type plasminogen activator receptor (UPA-R) in acute myeloid leukemia cells.
Castagnari B; Moretti S; Latorraca A; Rigolin GM; Balsamo R; Lanza F; Castoldi GL
Boll Soc Ital Biol Sper; 1995; 71(5-6):141-7. PubMed ID: 8519488
[TBL] [Abstract][Full Text] [Related]
4. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
5. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
Mizukami IF; Todd RF
J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
[TBL] [Abstract][Full Text] [Related]
6. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.
Béné MC; Castoldi G; Knapp W; Rigolin GM; Escribano L; Lemez P; Ludwig WD; Matutes E; Orfao A; Lanza F; van't Veer M;
Leukemia; 2004 Mar; 18(3):394-400. PubMed ID: 14671631
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H
J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577
[TBL] [Abstract][Full Text] [Related]
8. Expression and functional role of urokinase-type plasminogen activator receptor (UPA-R; CD87) in normal and acute leukemia cells.
Castagnari B; Moretti S; Latorraca A; Spisani S; Traniello S; Castoldi GL; Lanza F
Eur J Histochem; 1997; 41 Suppl 2():109-10. PubMed ID: 9859806
[No Abstract] [Full Text] [Related]
9. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils.
Plesner T; Ploug M; Ellis V; Rønne E; Høyer-Hansen G; Wittrup M; Pedersen TL; Tscherning T; Danø K; Hansen NE
Blood; 1994 Feb; 83(3):808-15. PubMed ID: 8298141
[TBL] [Abstract][Full Text] [Related]
10. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage.
Wohn KD; Kanse SM; Deutsch V; Schmidt T; Eldor A; Preissner KT
Thromb Haemost; 1997 Mar; 77(3):540-7. PubMed ID: 9066008
[TBL] [Abstract][Full Text] [Related]
11. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.
Jardí M; Inglés-Esteve J; Burgal M; Azqueta C; Velasco F; López-Pedrera C; Miles LA; Félez J
Thromb Haemost; 1996 Dec; 76(6):1009-19. PubMed ID: 8972026
[TBL] [Abstract][Full Text] [Related]
12. Clustering of urokinase receptors (uPAR; CD87) induces proinflammatory signaling in human polymorphonuclear neutrophils.
Sitrin RG; Pan PM; Harper HA; Todd RF; Harsh DM; Blackwood RA
J Immunol; 2000 Sep; 165(6):3341-9. PubMed ID: 10975852
[TBL] [Abstract][Full Text] [Related]
13. Function of the urokinase receptor (CD87) in neutrophil chemotaxis.
Gyetko MR; Sitrin RG; Fuller JA; Todd RF; Petty H; Standiford TJ
J Leukoc Biol; 1995 Nov; 58(5):533-8. PubMed ID: 7595054
[TBL] [Abstract][Full Text] [Related]
14. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activation in human acute leukaemias.
Scherrer A; Wohlwend A; Kruithof EK; Vassalli JD; Sappino AP
Br J Haematol; 1999 Jun; 105(4):920-7. PubMed ID: 10554801
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of different permeabilization methods for the flow cytometry measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukemic cells.
Lanza F; Latorraca A; Moretti S; Castagnari B; Ferrari L; Castoldi G
Cytometry; 1997 Jun; 30(3):134-44. PubMed ID: 9222099
[TBL] [Abstract][Full Text] [Related]
17. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
18. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
Ramage JG; Vallera DA; Black JH; Aplan PD; Kees UR; Frankel AE
Leuk Res; 2003 Jan; 27(1):79-84. PubMed ID: 12479856
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
[TBL] [Abstract][Full Text] [Related]
20. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
Hjertner O; Qvigstad G; Hjorth-Hansen H; Seidel C; Woodliff J; Epstein J; Waage A; Sundan A; Börset M
Br J Haematol; 2000 Jun; 109(4):815-22. PubMed ID: 10929035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
